/ Allgemein

G7 Finance Ministers’ Statement on Actions to Support Antibiotic Development


13.12.2021  G7 Finance Ministers met on the 13th December to agree on a statement of actions to support antibiotic development, highlighting the continued commitment of the G7 member states to solving the challenges facing the development of and access to the most needed existing and new antibiotics.

The Global AMR R&D Hub is honoured to be able to contribute, alongside the World Health Organisation (WHO), to the monitoring of development within the space, with a commitment to prepare a progress update for G7 Finance and Health Ministers in 2022. We look forward to taking on this challenge and seeing barriers being broken down that are currently hindering the preservation of and access to existing antibiotics, as well as the development of priority antibiotics, in tandem with a strengthening of the R&D landscape for antibiotic development.

Access the Policy Statement & annexes here.

Annual Report 2021 – now available!

09.11.2021 We have just published our ‘Annual Report 2021: The Global AMR R&D Funding Landscape’. The report provides a global snapshot of the AMR R&D activities across the full One Health spectrum, offering an evidence base to foster global priority setting and decision making on the allocation of resources. Access the full report here

Global Health Policy & Strategy Program Officer (m/f/d) – Berlin

07.12.2021: New job posting for a Global Health Policy & Strategy Program Officer. A great opportunity to be part of the Global AMR R&D Hub team in Berlin!

Apply by the 2nd January 2022.

Link to further details here:

Animal health R&D in LMICs

23.11.2021:  Antimicrobial resistance is a global public health threat that disproportionately affects low- and middle-income countries (LMICs). It presents risks to human health and also has severe implications for the health and welfare of animal populations, with major food security and environmental implications. IDRC and the Global AMR R&D Hub are pleased to publish a new report, which analyses the funding patterns of animal health AMR R&D in LMICs. In publishing this report, our two organizations hope to provide insight into investment and data gaps to inform the international community and provide evidence to help set future funding priorities in AMR research.

Link to report here.

Link to IDRC perspective piece: https://www.idrc.ca/en/perspectives/animal-AMR-funding-gaps

Joint Statement on Strengthening the Antibiotic R&D Pipeline by Rewarding Innovation

17.11.2021: 20 national and international organisations from academia, healthcare, global health and the pharmaceutical industry – including the Global AMR R&D Hub – appeal to G7 governments to step up efforts to tackle the growing problem of antibiotic resistance.

Read more here.

Cloud-based visualization of data serves science in the global fight against resistant pathogens

08.10.2021: Where science meets digitalization: the Global Antimicrobial Resistance Research and Development Hub, or Global AMR R&D Hub, works with huge amounts of research data from all around the world. In its mission to combat resistance to antimicrobial medication, the Hub needed a way of transparently documenting how research funding is used and make this information available to the public. The solution came in the form of a dynamic dashboard based on Microsoft Azure and Power BI. It will help highlight the scientific fields that need further research funding.

Access the full story here.

Public and philanthropic investments in AMR R&D related to animal health vaccines

30.08.2021: Antimicrobial resistance (AMR) not only poses a global threat to public health but also has severe implications for the health and welfare of animal populations. We are pleased to publish a new report that focuses on the current state of R&D funding for animal health vaccines. The collated data and observations arising provide a knowledge base that will aid decision makers in ensuring that public and philanthropic resources are targeting the most promising approaches and areas of greatest impact.

Special thanks to OIE and Health for Animals for their insights and contributions to this report.

Access the report here.

Study Publication: Estimating global market potential for priority health technologies addressing AMR

20.08.2021: One of the challenges inhibiting a more unified and co-ordinated global action in the field of incentives for AMR product development is a lack of evidence and data to quantify the scale of the required intervention. To help address this challenge, we established an Expert Advisory Group tasked with estimating the global market potential for products that they identified as representing some of the greatest unmet medical need for addressing AMR. We are proud to publish the outcomes of this study, which will help inform policy makers of the scale of this part of the AMR challenge and support current thinking on market intervention.

Download the full report and the accompanying policy briefs here.

New collaboration between ICARS and the Global AMR R&D Hub

Translating evidence into action!

12.07.2021: The Global AMR R&D Hub and ICARS are pleased to announce a new partnership that will further strengthen their efforts to translate evidence into action to mitigate antimicrobial resistance (AMR).

The collaboration will harness the power of the Global AMR R&D Hub’s Dynamic Dashboard to explore the current landscape of Operational and Implementation Research within low- and middle-income countries (LMICs), in an effort to connect AMR interventions with concrete outcomes. In doing so, the partners hope to be able to develop a pathway from knowledge to shape policy, programmes and practice.

Read the joint communication from ICARS and the Global AMR R&D Hub here.

The Dynamic Dashboard’s Pipeline Gallery updated to include the most recent analysis by PEW and the WHO

09.06.2021: The recent analysis of the global pipeline of antibacterials in clinical development from PEW and the WHO highlighted a stark picture of a broken antibiotics market unable to keep pace with the need for new drugs and that urgent action is needed to spur antibiotic innovation. This updated research has now been consolidated within the Dynamic Dashboard’s Pipeline Gallery, providing a tool to help policy makers and stakeholders monitor the antibacterial pipeline.  

Read the joint communication from PEW, WHO and the Global AMR R&D Hub here

Link to the Dynamic Dashboard providing a consolidated overview of the clinical pipeline from PEW and the WHO: Global AMR R&D Hub Dashboard (globalamrhub.org)